Lifeline Biotechnologies Overview
Valuation check: LLBO's PEG ratio is 67.62, above the Healthcare sector average of 2.56.
Get informed when a big investor buys or sells
+ Follow67.62
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for LLBO is 67.62. That is above the Healthcare sector average of 2.56. Investors often review this figure alongside Lifeline Biotechnologies's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, LLBO currently prints 67.62 for PEG ratio, while the sector average sits near 2.56. That is roughly 2541.7% above the sector mean. Large gaps often invite a closer look at Lifeline Biotechnologies's growth, margins, and balance sheet.
A PEG ratio of 67.62 for Lifeline Biotechnologies is not 'good' or 'bad' on its own. Compare it with the peer average (2.56) and with LLBO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting LLBO's PEG ratio (67.62), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Lifeline Biotechnologies's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
